For research and educational purposes only. Not medical advice.
Mecasermin Reference
Educational, not medical advice reference for Mecasermin: Growth Factor, Hormonal; regulatory status, evidence posture, source review, and schedule notes. Al…
Reference summary
Mecasermin is a label-verified recombinant human IGF-1 product with approved-label evidence in severe primary IGF-1 deficiency. pepSmart surfaces label-reference content only and explicitly does not endorse off-label muscle / performance / anti-aging use.
- Categories
- Growth Factor, Hormonal
- Aliases
- Increlex, rhIGF-1, Recombinant human IGF-1
- Evidence posture
- human - FDA-approved only for narrow pediatric severe-primary-IGF-1-deficiency indication. WADA-prohibited under category S2 at all times. Black-box-adjacent label warnings include severe hypoglycemia (with seizures), intracranial hypertension, lymphoid tissue hypertrophy (tonsillar/adenoidal), and a malignant neoplasia signal. Not the same compound as research-vial IGF-1 LR3 or IGF-1 DES.
- Regulatory status
- FDA-approved prescription medication (Increlex). Initial US approval 2005. Indicated for the treatment of growth failure in pediatric patients age 2 years and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion who have developed neutralizing antibodies to GH. Not indicated for secondary IGF-1 deficiency (GH deficiency, malnutrition, hypothyroidism, chronic anti-inflammatory corticosteroids), idiopathic short stature, or adult / off-label muscle / anti-aging use. WADA-prohibited under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) at all times. Prescription-only.
- Content review status
- label verified